

Brilliant Violet 605™ anti-human CD279 (PD-1) Antibody

Catalog# / Size	329923 / 25 tests 329924 / 100 tests
Clone	EH12.2H7
Regulatory Status	RUO
Other Names	PD-1
Isotype	Mouse IgG1, κ
Description	Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.

Product Details

Verified Reactivity	Human
Reported Reactivity	African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey
Antibody Type	Monoclonal
Host Species	Mouse
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration	Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is 5 μ l per million cells in 100 μ l staining volume or 5 μ l per 100 μ l of whole blood.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.

[Learn more about Brilliant Violet™.](#)

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Excitation Laser	Violet Laser (405 nm)
Application Notes	Additional reported applications (for the relevant formats) include: blocking of ligand binding ¹⁻

³, immunohistochemical staining of paraformaldehyde fixed frozen sections¹³, and spatial biology (IBEX)^{15,16}. The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/μg).

Application References

(PubMed link indicates BioLegend citation)

1. Dorfman DM, *et al.* 2006 *Am. J. Surg. Pathol.* 30:802. (FA)
2. Radziejewicz H, *et al.* 2007. *J. Virol.* 81:2545. (FA)
3. Velu V, *et al.* 2007. *J. Virol.* 81:5819. (FA)
4. Zahn RC, *et al.* 2008. *J. Virol.* 82:11577. [PubMed](#)
5. Chang WS, *et al.* 2008. *J. Immunol.* 181:6707. (FC) [PubMed](#)
6. Nakamoto N, *et al.* 2009. *PLoS Pathog.* 5:e1000313. (FA)
7. Jones RB, *et al.* 2009. *J. Virol.* 83:8722. (FC) [PubMed](#)
8. Vojnov L, *et al.* 2010. *J. Virol.* 84:753. (FC) [PubMed](#)
9. Radziejewicz H, *et al.* 2010. *J. Immunol.* 184:2410. (FC) [PubMed](#)
10. Montero P, *et al.* 2011. *J. Immunol.* 186:4618. [PubMed](#)
11. Conrad J, *et al.* 2011. *J. Immunol.* 186:6871. [PubMed](#)
12. Salisch NC, *et al.* 2010. *J. Immunol.* 184:476. (Rhesus reactivity)
13. Li H and Pauza CD. 2015. *Eur. J. Immunol.* 45:298. (IHC)
14. Peterson VM, *et al.* 2017. *Nat. Biotechnol.* 35:936. (PG)
15. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci USA.* 117:33455-33465. (SB) [PubMed](#)
16. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

Product Citations

1. Mo Y, *et al.* 2022. *Front Immunol.* 12:799896. [PubMed](#)
2. Eslamizar L, *et al.* 2021. *NPJ Vaccines.* 6:15. [PubMed](#)
3. Wijesinghe A, *et al.* 2020. *J Biomed Sci.* 27:50:00. [PubMed](#)
4. Arce Vargas F *et al.* 2018. *Cancer cell.* 33(4):649-663. [PubMed](#)
5. Bacher P, *et al.* 2020. *Immunity.* [PubMed](#)
6. Silva M, *et al.* 2021. *Sci Immunol.* 6:eabf1152. [PubMed](#)
7. Vetsika EK, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
8. Bending D, *et al.* 2014. *J Immunol.* 193:2699. [PubMed](#)
9. Kreutmair S, *et al.* 2021. *Immunity.* [PubMed](#)
10. You M, *et al.* 2021. *Nat Cell Biol.* 23:620. [PubMed](#)
11. Ferrando-Martinez S, *et al.* 2019. *JHEP Rep.* 0.159722222. [PubMed](#)
12. Hebbbar N, *et al.* 2022. *Nat Commun.* 13:587. [PubMed](#)
13. Xu S, *et al.* 2021. *Immunity.* [PubMed](#)
14. Rutishauser L, *et al.* 2017. *AIDS Res Hum Retroviruses.* 10.1089/AID.2016.0324. [PubMed](#)
15. Ellis-Connell AL, *et al.* 2018. *J Virol.* 92:e01748. [PubMed](#)
16. Del Alcazar D, *et al.* 2019. *Cell Rep.* 28:3047. [PubMed](#)
17. Maehara T, *et al.* 2018. *Life Sci Alliance.* 1:e201800050. [PubMed](#)
18. Collins DR, *et al.* 2021. *Immunity.* 54:2372. [PubMed](#)
19. Evgin L, *et al.* 2020. *Nat Commun.* 2.671527778. [PubMed](#)
20. Gorman JA, *et al.* 2019. *Front Immunol.* 10:44. [PubMed](#)
21. Halkias J, *et al.* 2019. *J Clin Invest.* 130:3562. [PubMed](#)
22. Cirelli KM *et al.* 2019. *Cell.* 177(5):1153-1171. [PubMed](#)
23. Pomplun NL, *et al.* 2021. *Cytometry A.* 99:278. [PubMed](#)
24. Salumets A, *et al.* 2022. *Aging Cell.* 21:e13607. [PubMed](#)
25. O'Connor MH, *et al.* 2021. *Commun Biol.* 4:563. [PubMed](#)
26. Fierle JK, *et al.* 2021. *Cell Reports Medicine.* 2(8):100362. [PubMed](#)
27. Trivedi S, *et al.* 2020. *Elife.* 9:00. [PubMed](#)

RRID

AB_11124107 (BioLegend Cat. No. 329923)
AB_2563212 (BioLegend Cat. No. 329924)

Antigen Details

Structure	Immunoglobulin superfamily
Distribution	Transiently expressed on CD4 ⁻ CD8 ⁻ thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells
Ligand/Receptor	B7-H1 (also known as PD-L1) and B7-DC (PD-L2)
Cell Type	B cells, Lymphocytes, T cells, Thymocytes, Tregs
Biology Area	Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family	CD Molecules, Immune Checkpoint Receptors
Gene ID	5133


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

Brilliant Violet 421™ anti-human CD279 (PD-1), Purified anti-human CD279 (PD-1), FITC anti-human CD279 (PD-1), PE anti-human CD279 (PD-1), APC anti-human CD279 (PD-1), Alexa Fluor® 647 anti-human CD279 (PD-1), PerCP/Cyanine5.5 anti-human CD279 (PD-1), APC/Cyanine7 anti-human CD279 (PD-1), Pacific Blue™ anti-human CD279 (PD-1), PE/Cyanine7 anti-human CD279 (PD-1), Purified anti-human CD279 (PD-1) (Maxpar® Ready), Brilliant Violet 605™ anti-human CD279 (PD-1), Ultra-LEAF™ Purified anti-human CD279 (PD-1), Brilliant Violet 711™ anti-human CD279 (PD-1), Brilliant Violet 785™ anti-human CD279 (PD-1), Brilliant Violet 510™ anti-human CD279 (PD-1), Biotin anti-human CD279 (PD-1), PE/Dazzle™ 594 anti-human CD279 (PD-1), Alexa Fluor® 488 anti-human CD279 (PD-1), PerCP anti-human CD279 (PD-1), GoInVivo™ Purified anti-human CD279 (PD-1), Brilliant Violet 650™ anti-human CD279 (PD-1), Alexa Fluor® 700 anti-human CD279 (PD-1), APC/Fire™ 750 anti-human CD279 (PD-1), TotalSeq™-A0088 anti-human CD279 (PD-1), TotalSeq™-B0088 anti-human CD279 (PD-1), TotalSeq™-C0088 anti-human CD279 (PD-1), Brilliant Violet 750™ anti-human CD279 (PD-1), TotalSeq™-D0088 anti-human CD279 (PD-1), PE/Fire™ 640 anti-human CD279 (PD-1), PE/Cyanine5 anti-human CD279 (PD-1)

Product Data



Human peripheral blood lymphocytes were stained with CD3 FITC and CD279 (clone EH12.2H7) Brilliant Violet 605™.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587